FIELD: medicine, pharmaceutics.
SUBSTANCE: offered is a new modified release dosage form of trimetazidine dihydrochloride in the form of an oral tablet which contains an active substance in amount 3.5 - 70.0 wt %, mixed povidone and polyvinyl acetate as a release modifier in amount 20.0 - 70.0 wt % and pharmaceutically acceptable pharmaceutical aids. Preferentially, the dosage form of trimetazidine dihydrochloride as mixed povidone and polyvinyl acetate contains Collidon SR.
EFFECT: invention shall allow to enlarge the range of high quality, available domestic modified release drugs.
18 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF OBTAINING MEDICAL FORM OF TRIMETAZIDINE OF PROLONGED ACTION | 2012 |
|
RU2530558C2 |
| PROLONGED PHARMACEUTICAL COMPOSITION DRUG FORM AND METHOD OF ITS PRODUCTION (VERSIONS) | 2009 |
|
RU2435584C2 |
| MATRIX TABLET WITH BASIS FOR TRIMETAZIDINE DIHYDROCHLORIDE RELEASE, WAY OF ITS RECEPTION AND WAY OF TREATMENT | 2007 |
|
RU2362548C1 |
| MEDICINAL FORMULATION ELICITING ANTI-ANGINAL EFFECT AND METHOD FOR ITS PREPARING | 2003 |
|
RU2260431C2 |
| MODIFIED RELEASE DOSAGE FORM OF TRIMETHAZIDIN AND METHOD FOR PREPARING THEREOF (VERSIONS) | 2008 |
|
RU2410097C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING AND USING DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION CONTAINING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2021 |
|
RU2818092C1 |
| DRUG FOR TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE AND METHOD FOR ITS OBTAINING | 2020 |
|
RU2749719C1 |
| PHARMACEUTICAL COMPOSITION OF FABOMOTIZOLE DIHYDROCHLORIDE | 2022 |
|
RU2828872C2 |
| DRUG BASED ON TETRAMETILTETRAAZOBITSIKLOOKTANDION AND METHOD FOR ITS PRODUCTION | 2012 |
|
RU2611194C2 |
| PROLONGED ACTION PHARMACEUTICAL COMPOSITION BASED ON 5-ETHOXY-2-[2-(MORPHOLINO)-ETHYLTHIO]BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE (APHOBAZOLUM) | 2017 |
|
RU2694837C2 |
